Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.
about
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerMitotoxicity in distal symmetrical sensory peripheral neuropathiesLifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivorsPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats.Therapeutic strategies for cancer treatment related peripheral neuropathies.The challenges of colorectal cancer survivorshipManagement of oxaliplatin-induced peripheral neuropathy.Low-level laser therapy alleviates mechanical and cold allodynia induced by oxaliplatin administration in rats.Oxaliplatin-associated neuropathy: a review.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Oxaliplatin-based chemotherapy in the management of colorectal cancer.National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Chemotherapy-induced peripheral neuropathy: prevention and treatment.Management options for established chemotherapy-induced peripheral neuropathy.Therapy-related peripheral neuropathy in multiple myeloma patients.Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.
P2860
Q24815800-6214A82B-D340-4562-B9AE-94D18E9E9087Q28834071-90D44AB7-C4E6-43C7-AC75-021E3EEA3CB5Q30234847-8F1D8193-107A-49E4-807F-84328433BBD2Q33693343-60152F81-9097-4423-B2BA-53577D9F913EQ33744706-5732F6DA-9A2D-4E7B-AFCD-ECFF249B6BE3Q34380468-6F8B74FC-5C45-42D0-BF5F-5A16E8A26FC9Q34433406-8EEB2D05-FDEA-409D-B811-21ED5953DCE8Q35032967-FD388F84-AF1D-4A2D-86DE-DB4FB73DA291Q35166744-88D16754-7094-4F56-ACD7-59EBDB4095C6Q35640591-097A8E62-6E65-4BF7-80F4-64B53611B285Q35980222-EBC55F84-57F7-4C09-B832-3F5A5AC5494DQ36226275-3F406798-02E8-4315-8E62-46B054A59106Q37242664-B11DD4AE-4424-4C0A-9E1D-AD962A0C30CEQ37364316-A3F84E17-F3A4-4F85-A7C7-C16E8E80A69CQ37399781-816B66B4-2FC1-424A-9392-5F7F4B1147ABQ37911252-8FE594EE-FBD0-4A06-9AD3-2878E069FC78Q38216217-441DBDAC-CFF2-4217-A397-53FC28C69745Q38268525-1D8A2298-64DD-43A1-9B36-5450FCF7A902Q39289330-5C58B244-03C9-4DE8-9404-2A5F0B4F029FQ39406087-5BFC8694-F206-4EB5-8D21-B87419A1FA06Q40540785-D2867F58-105F-4363-A138-D1670D2EB6AB
P2860
Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@en
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@nl
type
label
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@en
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@nl
prefLabel
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@en
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@nl
P2093
P356
P1476
Effective treatment of oxalipl ...... opathy with alpha-lipoic acid.
@en
P2093
C Gedlicka
G V Kornek
W Scheithauer
P304
P356
10.1200/JCO.2002.99.502
P407
P577
2002-08-01T00:00:00Z